If you zoomed in far enough on a new experimental HIV vaccine, you wouldn’t see the usual protein shell that most vaccines rely on. Instead, you’d find tiny geometric structures folded from strands of DNA—molecular origami designed not to be noticed at all. This “invisible” scaffold may be the key to awakening some of the rarest and most sought‑after cells in immunology: the B cells capable of maturing into broadly neutralizing antibody producers. Many next‑generation vaccines use virus‑like particles (VLPs)—nanostructures that mimic the outer shape of a virus but contain no genetic material. By displaying many copies of a viral antigen on their surface, VLPs can activate B cells far more effectively than free‑floating proteins. The paper is titled “DNA origami vaccines program antigen-focused germinal centers,” and was published recently in Science. Broadly neutralizing antibodies, or bnAbs, are a long‑standing goal of HIV vaccine research because they can disable many strains of the virus at once. HIV mutates so quickly that most antibodies recognize only a single strain, which is why researchers have long sought broadly neutralizing antibodies that target conserved regions of the virus. But bnAbs target deeply conserved regions of the virus—sites HIV can’t easily change without compromising itself. The challenge is that the B cells capable of evolving into bnAb‑producing cells are extraordinarily rare, and they’re easily drowned out by other immune responses. That’s where the new DNA‑based vaccine platform comes in. Developed by researchers at MIT and Scripps Research Institute, the vaccine uses DNA instead of a…
